Nykode Therapeutics enters multi-target license and collaboration agreement with Regeneron
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
The week-long campaign received a record 17.691 pledges
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
The programme will be implemented across 13 states and benefit 256 min
The approval is for Cytomegalovirus, a type of Herpes virus
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Subscribe To Our Newsletter & Stay Updated